Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info


P: 267-440-4200 F: 267-440-4242


Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

Key Statistics


Market Capitalization, $K 318,610
Shares Outstanding, K 98,034
Annual Sales, $ 30,480 K
Annual Net Income, $ -96,970 K
Last Quarter Sales, $ 2,830 K
Last Quarter Net Income, $ -29,220 K
60-Month Beta 1.70
% of Insider Shareholders 7.90%
% of Institutional Shareholders 46.01%
Float, K 90,289
% Float 92.10%


1-Year Return -32.64%
3-Year Return -69.27%
5-Year Return -63.78%
5-Year Revenue Growth 126.28%
5-Year Earnings Growth -118.75%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 05/09/19
Earnings Per Share ttm -0.99
EPS Growth vs. Prev Qtr 11.76%
EPS Growth vs. Prev Year 16.67%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-4 on 06/06/14

INO Ratios

Price/Earnings ttm 0.00
Price/Earnings forward -5.73
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -97.95
Return-on-Assets (Before Tax) -61.34
Profit Margin % -318.14
Net Margin % -141.23
Debt/Equity 0.00
Price/Sales 10.45
Price/Cash Flow N/A
Price/Book 3.92
Book Value/Share 0.83
Interest Coverage N/A
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar